DCPH News and Press, Deciphera Pharmaceuticals Inc. From 02/11/22

Deciphera's ripretinib failed a critical trial. The stock has been decimated. Although the company is struggling to make a comeback, it will take time. For further details see: Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2021 Earnings Conference Call February 08, 2022, 04:30 PM ET Company Participants Maghan Meyers - SVP, Argot Partners Steve Hoerter - President and CEO Dan Martin - Chief Commercial Officer Tucker Kelly - CFO Conference Call Participants Jessica Fye -...

Deciphera Pharmaceuticals press release (NASDAQ:DCPH): Q4 GAAP EPS of -$1.51 misses by $0.03. Revenue of $24.2M (+24.2% Y/Y) beats by $0.92M. For further details see: Deciphera Pharmaceuticals GAAP EPS of -$1.51 misses by $0.03, revenue of $24.2M beats by $0.92M

– Fourth Quarter 2021 Revenue of $24.2 Million and Full Year 2021 Revenue of $96.1 Million – – Launch of QINLOCK ® in Europe Underway – – Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT Patients Underway; Updated Phase 1/...

Deciphera Pharmaceuticals (NASDAQ:DCPH) is scheduled to announce Q4 earnings results on Tuesday, February 8th, after market close. The consensus EPS Estimate is -$1.40 and the consensus Revenue Estimate is $23.28M (+19.4% Y/Y). Over the last 3 months, EPS estimates have seen 3 upward revision...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022. In connection with the earnings release, Deciphera’s management team will host a live conference call and w...

– Efficacy Observed with QINLOCK ® was Comparable to Sunitinib with a More Favorable Safety and Tolerability Profile in GIST Patients Previously Treated with Imatinib – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceu...

– Launch of QINLOCK ® in Germany Underway; Transition to Post-approval Paid Access Program in France Expected in 1H 2022 – – Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT Patients Underway; Updated Phase 1/2 Data Expected in 2H 2022 –...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 9:00 AM ET. A live webcast of the event will be avail...

Deciphera Pharmaceuticals (NASDAQ:DCPH) perks up 3.7% premarket following an announcement that the U.K.'s Medicines and Healthcare products Regulatory Agency has granted marketing authorization for Qinlock (ripretinib) for the treatment of adult patients with advanced gastroint...